S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
S&P 500   2,584.59 (-1.60%)
DOW   21,917.16 (-1.84%)
QQQ   190.40 (-0.85%)
AAPL   254.29 (-0.20%)
FB   166.80 (+0.51%)
MSFT   157.71 (-1.57%)
GOOGL   1,161.95 (+1.36%)
AMZN   1,949.72 (-0.72%)
CGC   14.42 (-0.28%)
NVDA   263.60 (-0.75%)
BABA   194.48 (+1.68%)
MU   42.06 (-5.53%)
GE   7.94 (+0.63%)
TSLA   524.00 (+4.36%)
AMD   45.48 (-4.97%)
T   29.15 (-3.57%)
ACB   0.91 (+2.26%)
F   4.83 (-3.98%)
NFLX   375.50 (+1.22%)
BAC   21.23 (-3.68%)
GILD   74.76 (-1.54%)
PRI   88.48 (-2.46%)
DIS   96.60 (-3.21%)
Log in

OTCMKTS:NWBO - Northwest Biotherapeutics Stock Price, Forecast & News

$0.16
+0.01 (+3.90 %)
(As of 03/31/2020 04:00 PM ET)
Today's Range
$0.14
Now: $0.16
$0.16
50-Day Range
$0.15
MA: $0.18
$0.27
52-Week Range
$0.14
Now: $0.16
$0.35
Volume2.10 million shs
Average Volume1.71 million shs
Market Capitalization$105.60 million
P/E RatioN/A
Dividend YieldN/A
Beta1.29
Northwest Biotherapeutics, Inc., a biotechnology company, discovers and develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It is developing DCVax-L, a product in Phase III clinical trials to treat Glioblastome multiforme, a brain cancer; and DCVax-Direct, a product in Phase I/II clinical trials to treat various types of inoperable solid tumor cancers. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
Read More

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:NWBO
Previous SymbolNASDAQ:NWBO
CUSIPN/A
Phone240-497-9024

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.41 million
Book Value($0.07) per share

Profitability

Net Income$-20,300,000.00
Net Margins-842.16%

Miscellaneous

Employees14
Market Cap$105.60 million
Next Earnings Date5/8/2020 (Estimated)
OptionableNot Optionable

Receive NWBO News and Ratings via Email

Sign-up to receive the latest news and ratings for NWBO and its competitors with MarketBeat's FREE daily newsletter.


Northwest Biotherapeutics (OTCMKTS:NWBO) Frequently Asked Questions

How has Northwest Biotherapeutics' stock been impacted by COVID-19 (Coronavirus)?

Northwest Biotherapeutics' stock was trading at $0.1799 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NWBO stock has decreased by 11.1% and is now trading at $0.16. View which stocks have been mosted impacted by Coronavirus.

When is Northwest Biotherapeutics' next earnings date?

Northwest Biotherapeutics is scheduled to release its next quarterly earnings announcement on Friday, May 8th 2020. View our earnings forecast for Northwest Biotherapeutics.

How were Northwest Biotherapeutics' earnings last quarter?

Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) announced its quarterly earnings results on Monday, March, 16th. The biotechnology company reported $0.01 EPS for the quarter. The biotechnology company earned $0.90 million during the quarter. View Northwest Biotherapeutics' earnings history.

Has Northwest Biotherapeutics been receiving favorable news coverage?

News stories about NWBO stock have trended positive on Tuesday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Northwest Biotherapeutics earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutNorthwest Biotherapeutics.

Who are some of Northwest Biotherapeutics' key competitors?

What other stocks do shareholders of Northwest Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Northwest Biotherapeutics investors own include Clearside Biomedical (CLSD), Ocular Therapeutix (OCUL), Melinta Therapeutics (MLNT), Zeltiq Aesthetics (ZLTQ), Avid Bioservices (CDMO), Amarin (AMRN), TransEnterix (TRXC), Kura Oncology (KURA), Novavax (NVAX) and Synergy Pharmaceuticals (SGYP).

Who are Northwest Biotherapeutics' key executives?

Northwest Biotherapeutics' management team includes the following people:
  • Ms. Linda F. Powers J.D., Chairperson, CEO, Pres & CFO (Age 63)
  • Dr. Alton L. Boynton, Founder, Chief Scientific Officer, Sec. & Director (Age 74)
  • Dr. Marnix L. Bosch M.B.A., Ph.D., MBA, Chief Technical Officer (Age 60)
  • Mr. Leslie J. Goldman, Sr. VP & Gen. Counsel (Age 74)
  • Mr. David Innes, VP of Investor Relations

What is Northwest Biotherapeutics' stock symbol?

Northwest Biotherapeutics trades on the OTCMKTS under the ticker symbol "NWBO."

How do I buy shares of Northwest Biotherapeutics?

Shares of NWBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Northwest Biotherapeutics' stock price today?

One share of NWBO stock can currently be purchased for approximately $0.16.

How big of a company is Northwest Biotherapeutics?

Northwest Biotherapeutics has a market capitalization of $105.60 million and generates $2.41 million in revenue each year. Northwest Biotherapeutics employs 14 workers across the globe. View additional information about Northwest Biotherapeutics.

What is Northwest Biotherapeutics' official website?

The official website for Northwest Biotherapeutics is http://www.nwbio.com/.

How can I contact Northwest Biotherapeutics?

Northwest Biotherapeutics' mailing address is 4800 MONTGOMERY LANE SUITE 800, BETHESDA MD, 20814. The biotechnology company can be reached via phone at 240-497-9024 or via email at [email protected]


MarketBeat Community Rating for Northwest Biotherapeutics (OTCMKTS NWBO)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  161 (Vote Outperform)
Underperform Votes:  146 (Vote Underperform)
Total Votes:  307
MarketBeat's community ratings are surveys of what our community members think about Northwest Biotherapeutics and other stocks. Vote "Outperform" if you believe NWBO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NWBO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel